Robert J. Hombach

Robert (Bob) Hombach is a retired CFO & COO with 27 years of financial and operational leadership experience in the healthcare sector, and serves as a Board Member on the Audit, Finance and Compensation committees for a number of public and private boards.

Most recently, Hombach served as Executive Vice President, Chief Financial Officer & Chief Operations Officer for Baxalta (NYSE: BXLT), a $6B global bio-pharmaceutical company spun off from its parent, Baxter (NYSE: BAX), in 2015. He drove the process to successfully launch the Company post-spin and subsequently played a key role in leading Baxalta’s defense against an unsolicited $32B hostile bid from Shire PLC, which resulted in exceptional value for shareholders.

Before Baxalta, Hombach served as Corporate Vice President and CFO for Baxter International (2010– 2015) and drove the strategic process to split up Baxter. He also had oversight of the company’s venture capital investments through the $200M Baxter Ventures Fund.

Hombach currently serves on the Board of Directors of BioMarin (BMRN), a leading biotechnology company in rare diseases and gene therapy, as Chair of the Audit Committee. He also serves on the Board of Embecta (EMBC), which was spun out of Becton Dickinson in April 2022, as its Chair of the Audit Committee; and he serves on the Board of Seaport Therapeutics, a pre-IPO clinical stage biotech company focused on novel antidepressants and anxiolytics based on clinically validated mechanisms powered by its propriety Glyph platform.

Previously, he served on the Board of Aptinyx (APTX), a clinical stage biopharmaceutical company focused on neurological disorders as Chair of the Audit Committee; he served on the Board of Naurex, Inc., a private pharmaceuticals company acquired by Allergan in 2015 for $560M; and he served on the Board of Surgical Innovation Associates (SIA), a private company in the surgical mesh space, which was sold to Integra LifeSciences for $140M in December 2022.

Hombach earned an MBA from Northwestern University’s JL Kellogg School of Management, and a BS in Finance cum Laude from the University of Colorado. He earned the Certified Public Accountant (CPA) designation and was an Elijah Watt Sells Award Winner on the November 1990 CPA exam, and earned the Certified Management Accountant (CMA) designation in 1994. He was recognized by IR Magazine as a Top 100 US CFO (ranked #7 in both 2013 & 2014) as voted on by institutional investors across all industries. He was recognized as a Board Leadership Fellow by the National Association of Corporate Directors (NACD).